Prenen H, Deva S, Keam B, Lindsay CR, et al. Phase II study to determine the anti-tumor activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in esophageal cancer. Clin Cancer Res 2024 May 6. doi: 10.1158/1078-0432.CCR-23-2677.
PMID: 38709220